BACKGROUND: HIV patients are at increased cardiovascular risk while available European cardiovascular recommendations are ambiguous. METHODS: Retrospective analysis of 389 HIV-patients was conducted. Cardiovascular risk was determined by D:A:D, Framingham and SCORE scales. Patients were divided into risk groups as recommended by EACS 2019, PTN AIDS 2019 and ESC/EAS 2019 Guidelines and hypolipemic treatment was evaluated. RESULTS: In total, 389 HIV-positive patients took part in the study, most of whom were men (n = 312, 80.4%), mean age 41.69±10years. Mean lipid levels among all HIV patients: Tch:177.2±36mg/dl, HDL:48.9±18mg/dl, LDL:103.8±31mg/dl, TG:143.3±81mg/dl, AIP:0.45±0.3, non-HDL:129.2±36 mg/dl. Most of the participants (n = 360, 92.5%) were assigned to the high cardiovascular risk group according to ESC/EAS and PTN AIDS guidelines. The achievement of therapeutic LDLs according to ESC/EAS was 10.3% for those at very high cardiovascular risk (8.7% on lipid lowering treatment vs. 16.7% without hypolipemic drugs) and 12.0% (5.8% treated vs. 13.6% untreated) at high cardiovascular risk; according to PTN AIDS,17.2% achievement was noted by the very high-risk group (13% treated vs. 33.3% untreated), and 45.9% for the high-risk group (37.7% treated vs. 48.0% untreated); according to EACS Guidelines, 2.5% achievement in secondary prevention (3.8% treatedvs. 0% untreated) and 24.7% in primary prevention (22.2% treated vs. 26.1% untreated). Mean doses of statins were 8.75mg±6mg (Rosuvastatin) and 22.35±19mg (Atorvastatin). CONCLUSIONS: The achievement of therapeutic LDLs by all recommendations is unsatisfactory, and generally worse in patients on lipid lowering therapy. Hypolipemic treatment of our HIV patients is based on low doses of statins, even in secondary prevention.
BACKGROUND:HIVpatients are at increased cardiovascular risk while available European cardiovascular recommendations are ambiguous. METHODS: Retrospective analysis of 389 HIV-patients was conducted. Cardiovascular risk was determined by D:A:D, Framingham and SCORE scales. Patients were divided into risk groups as recommended by EACS 2019, PTN AIDS 2019 and ESC/EAS 2019 Guidelines and hypolipemic treatment was evaluated. RESULTS: In total, 389 HIV-positive patients took part in the study, most of whom were men (n = 312, 80.4%), mean age 41.69±10years. Mean lipid levels among all HIVpatients: Tch:177.2±36mg/dl, HDL:48.9±18mg/dl, LDL:103.8±31mg/dl, TG:143.3±81mg/dl, AIP:0.45±0.3, non-HDL:129.2±36 mg/dl. Most of the participants (n = 360, 92.5%) were assigned to the high cardiovascular risk group according to ESC/EAS and PTN AIDS guidelines. The achievement of therapeutic LDLs according to ESC/EAS was 10.3% for those at very high cardiovascular risk (8.7% on lipid lowering treatment vs. 16.7% without hypolipemic drugs) and 12.0% (5.8% treated vs. 13.6% untreated) at high cardiovascular risk; according to PTN AIDS,17.2% achievement was noted by the very high-risk group (13% treated vs. 33.3% untreated), and 45.9% for the high-risk group (37.7% treated vs. 48.0% untreated); according to EACS Guidelines, 2.5% achievement in secondary prevention (3.8% treatedvs. 0% untreated) and 24.7% in primary prevention (22.2% treated vs. 26.1% untreated). Mean doses of statins were 8.75mg±6mg (Rosuvastatin) and 22.35±19mg (Atorvastatin). CONCLUSIONS: The achievement of therapeutic LDLs by all recommendations is unsatisfactory, and generally worse in patients on lipid lowering therapy. Hypolipemic treatment of our HIVpatients is based on low doses of statins, even in secondary prevention.
Authors: Neil J Stone; Jennifer G Robinson; Alice H Lichtenstein; C Noel Bairey Merz; Conrad B Blum; Robert H Eckel; Anne C Goldberg; David Gordon; Daniel Levy; Donald M Lloyd-Jones; Patrick McBride; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Karol Watson; Peter W F Wilson Journal: J Am Coll Cardiol Date: 2013-11-12 Impact factor: 24.094
Authors: Virginia A Triant; Jeremiah Perez; Susan Regan; Joseph M Massaro; James B Meigs; Steven K Grinspoon; Ralph B D'Agostino Journal: Circulation Date: 2018-02-14 Impact factor: 29.690
Authors: Sara Croxford; Aileen Kitching; Sarika Desai; Meaghan Kall; Michael Edelstein; Andrew Skingsley; Fiona Burns; Andrew Copas; Alison E Brown; Ann K Sullivan; Valerie Delpech Journal: Lancet Public Health Date: 2016-12-15
Authors: Greer A Burkholder; Paul Muntner; Hong Zhao; Michael J Mugavero; E Turner Overton; Meredith Kilgore; Daniel R Drozd; Heidi M Crane; Richard D Moore; Wm Christopher Mathews; Elvin Geng; Stephen Boswell; Michelle Floris-Moore; Robert S Rosenson Journal: J Clin Lipidol Date: 2018-03-29 Impact factor: 5.365
Authors: Rosan A van Zoest; Marc van der Valk; Ferdinand W Wit; Ilonca Vaartjes; Katherine W Kooij; Joppe W Hovius; Maria Prins; Peter Reiss Journal: Eur J Prev Cardiol Date: 2017-06-05 Impact factor: 7.804
Authors: Piotr Bandosz; Martin O'Flaherty; Wojciech Drygas; Marcin Rutkowski; Jacek Koziarek; Bogdan Wyrzykowski; Kathleen Bennett; Tomasz Zdrojewski; Simon Capewell Journal: BMJ Date: 2012-01-25
Authors: Anastasia V Poznyak; Evgeny E Bezsonov; Evgeny E Borisov; Andrey V Grechko; Andrey G Kartuesov; Alexander N Orekhov Journal: Int J Mol Sci Date: 2022-02-24 Impact factor: 5.923